TransMedics Group (NasdaqGM:TMDX) received full FDA approval for its Next-Generation OCS ENHANCE Heart trial. The decision ...

Add Yahoo as a preferred source to see more of our stories on Google. Part B aims to expand clinical indications for OCS Heart to include standard criteria DBD hearts transplanted within four hours.

ANDOVER, Mass., Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. (TMDX) ("TransMedics"), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung ...

ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

ANDOVER, Mass., April 2, 2025 /PRNewswire/ -- TransMedics Group, Inc. (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and ...

Shares of next-generation transplant technology platform TransMedics (NASDAQ: TMDX) were up 21% as of noon ET on Friday, according to data provided by S&P Global Market Intelligence. TransMedics ...

TransMedics Group, Inc. (NASDAQ:TMDX) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 4, TransMedics Group, Inc. (NASDAQ:TMDX) received conditional approval ...

Is TMDX a good stock to buy? We came across a bullish thesis on TransMedics Group, Inc. on The Cash Flow Compounder’s Substack. In this article, we will summarize the bulls’ thesis on TMDX.

TransMedics continues to reinvent the organ transplant industry, but the market insists the stock is "overvalued" now.

TransMedics Group, Inc. (NASDAQ:TMDX) is one of the best under-the-radar stocks to buy according to hedge funds. On February 25, Baird raised its price target on TransMedics Group, Inc. (NASDAQ:TMDX) ...

TransMedics grew sales by 38% during the second quarter and saw its profit margins double compared to last year. Despite this, there may still be room for improvement, according to its CEO.